| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/JAC/27.3.369 |
| P698 | PubMed publication ID | 2037541 |
| P2093 | author name string | Rozenberg-Arska M | |
| Verhoef J | |||
| Dekker AW | |||
| Branger J | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| amphotericin B | Q412223 | ||
| fluconazole | Q411478 | ||
| P304 | page(s) | 369-376 | |
| P577 | publication date | 1991-03-01 | |
| P1433 | published in | Journal of Antimicrobial Chemotherapy | Q6294770 |
| P1476 | title | A randomized study to compare oral fluconazole to amphotericin B in the prevention of fungal infections in patients with acute leukaemia | |
| P478 | volume | 27 |
| Q77742205 | A randomized comparison of fluconazole with amphotericin B as empiric anti-fungal agents in cancer patients with prolonged fever and neutropenia |
| Q30431307 | A systematic review of oral fungal infections in patients receiving cancer therapy. |
| Q24193785 | Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patients |
| Q30887333 | Amphotericin B vs fluconazole for controlling fungal infections in neutropenic cancer patients |
| Q37009912 | Antifungal management in cancer patients |
| Q35374928 | Antifungal prophylaxis during neutropenia and immunodeficiency |
| Q44062340 | Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials |
| Q35234790 | Antifungal treatment strategy in leukemia patients |
| Q59650052 | Antimycotics |
| Q54040897 | Comparative study of the efficacy of fluconazole versus amphotericin B/flucytosine in surgical patients with systemic mycoses. |
| Q72294195 | Comparison of fluconazole with oral polyenes in the prevention of fungal infections in neutropenic patients. A prospective, randomized, single-center study |
| Q40774502 | Critical appraisal of antimicrobials for prevention of infections in immunocompromised hosts. |
| Q40575644 | Early infections in adults undergoing matched related and matched unrelated/mismatched donor stem cell transplantation: a comparison of incidence |
| Q34490092 | Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? |
| Q67864160 | Fluconazole prophylaxis of recurrent oral candidiasis in HIV-positive patients |
| Q33608832 | Fluconazole versus itraconazole for the prevention of fungal infections in haemato-oncology |
| Q44556457 | Hepatosplenic candidasis, a fatal disease? |
| Q24243005 | Interventions for preventing oral candidiasis for patients with cancer receiving treatment |
| Q24246168 | Interventions for preventing oral candidiasis for patients with cancer receiving treatment |
| Q34071588 | Management of fungal infections in neutropenic patients: more doubts than certainties? |
| Q71965388 | Orointestinal yeast colonization of paediatric bone marrow transplant recipients: surveillance by quantitative culture and serology |
| Q37344532 | Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. |
| Q39866778 | Strategies in prevention of invasive pulmonary aspergillosis in immunosuppressed or neutropenic patients |
| Q35196514 | The Use of Fluconazole Prophylaxis in Patients with Chemotherapy-Induced Neutropenia |
| Q31893406 | The combination of oral amphotericin B with azoles prevents the emergence of resistant Candida species in neutropenic patients. |
| Q70688931 | The prophylactic use of fluconazole 50 vs. 100 mg daily in haematological malignancies |
| Q34022479 | Towards a targeted, risk-based, antifungal strategy in neutropenic patients |
| Q36767158 | Use of prophylactic antifungals in the immunocompromised host. |
| Q34517297 | Weekly use of fluconazole as prophylaxis in haematological patients at risk for invasive candidiasis |
| Q43952852 | Why prior fluconazole use is associated with an increased risk of invasive mold infections in immunosuppressed hosts: an alternative hypothesis |
| Q73274282 | [Preventive antimycotic therapy of neutropenic and immunosuppressed patients] |
Search more.